The brief

Analyst view

• Cognito's Spectris AD uses 40 Hz light and sound stimulation to target neurodegeneration in Alzheimer's disease.
• The HOPE pivotal trial enrolled 670 patients to evaluate disease-modifying effects in early cognitive decline.
• Series C funding of $105 million in March 2026 funds the pivotal trial and late-stage development.

Technical approach

As reported

Gammawave stimulation

40 Hz light and sound targeting brain oscillations

Cognito uses synchronized light and sound at 40 Hz to drive neural oscillations thought to enhance amyloid clearing in Alzheimer's disease.

Non-invasive

Wearable delivery with no brain implants

The system uses external light and sound sources, making it non-invasive and safe for chronic home use by elderly patients.

Disease-modifying intent

Targeting early cognitive decline

Spectris AD targets the mild cognitive impairment and early dementia stages before irreversible brain loss, when intervention has the best chance.